Novak, Urban
Mooyaart, Jarl E.
Daskalakis, Michael http://orcid.org/0000-0002-8138-0505
Scheid, Christof
Gabellier, Ludovic
Yakoub-Agha, Ibrahim
Ram, Ron http://orcid.org/0000-0001-8683-6930
Forcade, Edouard
López-Corral, Lucía
Nicholson, Emma http://orcid.org/0000-0002-6439-0795
Galli, Eugenio http://orcid.org/0000-0002-2839-916X
Stölzel, Friedrich http://orcid.org/0000-0003-0653-5332
Bethge, Wolfgang http://orcid.org/0000-0001-6052-2618
Wagner-Drouet, Eva Maria http://orcid.org/0000-0002-0728-2253
Hoogenboom, Jorinde D.
Mielke, Stephan
Arber, Caroline http://orcid.org/0000-0001-6440-9970
Simonetta, Federico http://orcid.org/0000-0002-0399-689X
Chabannon, Christian http://orcid.org/0000-0002-3755-4889
Kuball, Jürgen http://orcid.org/0000-0002-3914-7806
Ruggeri, Annalisa
Malard, Florent http://orcid.org/0000-0002-3474-0002
Article History
Received: 24 June 2024
Revised: 9 August 2024
Accepted: 13 August 2024
First Online: 27 August 2024
Competing interests
: FS: travel Support from Janssen, medac; honoraria from medac, GWT, Abbvie, Servier, Pierre Fabre; research funding from medac, Servier. CA: institutional consulting fees through CHUV from Gilead, Janssen, Celgene/ BMS; institutional sponsored travel through CHUV from Gilead; institutional licensing fees and royalties through previous institution Baylor College of Medicine from Immatics; patents and provisional patent applications in the field of engineered T cell therapies. FS: institutional consulting fees from BMS/Celgene, Incyte, Kite/Gilead; speaker fees from Kite/Gilead, Incyte; travel support from Kite/Gilead, Novartis, AstraZeneca, Neovii, Janssen; research funding from Kite/Gilead, Novartis, BMS/Celgene. CC: Institutional / personal honoraria and travel funding from BMS, Janssen, Jazz, Kite / Gilead, Miltenyi biotec, Novartis. JK: research support from Novartis, Miltenyi Biotech, Gadeta. Florent Malard: honoraria from BMS, Therakos/Mallinckrodt, Sanofi, JAZZ Pharmaceuticals, Gilead, Novartis, AstraZeneca and MSD, all outside the submitted work. The other authors declare no competing financial interests.